1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. CRYPTOCOCCOSIS THERAPEUTICS MARKET BY TREATMENT
5.1. Introduction
5.2. Amphotericin B
5.3. Flucytosine
5.4. Fluconazole Drugs
5.5. Voriconazole
6. CRYPTOCOCCOSIS THERAPEUTICS MARKET BY DIAGNOSTIC
6.1. Introduction
6.2. Cryptococcal Antigen
6.3. Chest X-ray
6.4. Lumbar Puncture
6.5. Urine Test
7. CRYPTOCOCCOSIS THERAPEUTICS MARKET BY END-USER
7.1. Introduction
7.2. Hospitals
7.3. Ambulatory Surgical Centers
7.4. Others
8. CRYPTOCOCCOSIS THERAPEUTICS MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Gilead Sciences
10.2. Cureus
10.3. VIC Health
10.4. Astellas Pharma Inc.
10.5. Novartis AG
10.6. Pfizer Inc.
10.7. Glenmark Pharmaceuticals
10.8. Lupin Ltd.
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES